Two studies examining relationships between measures of kidney function and adverse events after platinum-based chemotherapy were presented as late-breaking abstracts at the National Kidney Foundation ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Enfortumab vedotin is now available for patients who received prior platinum-containing chemotherapy and a PD-1/L1 inhibitor ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Cadonilimab plus lenvatinib showed promising antitumor activity in patients with advanced endometrial cancer who have experienced disease progression after prior platinum-based chemotherapy,” said ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

In a paper published in MedComm, an international team of scientists provided an overview of the advancements in the ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...